Medinol CE-marks pre-mounted NIRFLEX stent:
This article was originally published in Clinica
Executive Summary
Israeli company Medinol has gained CE-mark approval to sell its next-generation, pre-mounted NIRFLEX coronary and peripheral stent in an estimated $500 million European marketplace. The device, which is based on a uniform matrix closed cell design, provides an optimal platform for the even release of drugs that are intended to prevent restenosis, says Medinol. Additionally, the Jerusalem-based firm has gained US FDA go-ahead to begin recruitment into US trials of the NIRFLEX stent, which are scheduled to begin in May this year.